Recombinetics, a pioneer in solutions for gene processing for human health and
animal farming, nowadays Mark Platt, the head of the organization
Executive Officer.

"Recombinetics leads the way in innovative research and
development to tackle problems of global significance, such as feeding it
hunger, improving the health of the population and the humane treatment of
animals, "says Platt." I take part in this transformational time
ensure that the organization and its strategic investors do well, with everyone
tailored to positively influence people, places and animals at home

"Our organization will benefit greatly from Mark's leadership
experience ", says Peter Hajas, chairman of the board of directors, Recombinetics.
"Mark brings enthusiasm for the possibilities of our innovative work
and is the right person to guide and nurture our corporate culture
relationships with key stakeholders to achieve goals to improve people
lives, feeds the growing population of the world and reduces the animal

Platt's experience includes his time as president and CEO of Multistack,
LLC, in Sparta, Wis., Where it provided the strategic long-term direction
the company and was directly involved in emerging technology, research
and development. From 2002 to 2012 Mark led the company through his
highest growth period, with a total sales increase of more than
1,000 percent.

Most recently Executive Sales Leader at the Midwest sales of Trane, Inc.
office, Platt played a role in doubling the market share of the organization
in less than two years. He was also Senior Vice President of Business
Services for Gundersen Health System from November 2013 to April 2017.
In this role, Platt supervised business development and marketing,
government relations, supply chain, facility operations and community
wellness initiatives. He also served on the board of Gundersen from

Platt has earned his bachelor's degree in electrical engineering
Vanderbilt University, Nashville, Tenn. He also had an assignment
officer in the US Air Force with 17 years of service and retained the rank
from captain in the US Air Force Reserve.

Tammy Lee, who had been president and CEO of Recombinetics since August
2017, says goodbye to the company. Recombinetics
thanks Lee for her leadership, including securing $ 34 million
the Series A financing round of the company.

About Recombinetics

Founded in 2008, Recombinetics (RCI) has
a single technology platform for gene processing that supports three companies
lines: Acceligen (precision culture for health, well-being and
productivity in food and aquaculture); Surrogen (gene-edited
pig models of human diseases for biomedical research and pre-clinical research
investigations by pharmaceutical and medical device companies); and Regenevida
(development of regenerative human products, including cells, tissues and
organ products in pig models for exotransplantation to humans).

Recombinetics has a global portfolio for intellectual property, with 22
patents granted and more than 300 patent applications on methods for gene processing,
characteristics and new reproduction methods in animals. More information

View the source version on

SOURCE: Recombinetics ">
<Property FormalName = "PrimaryTwitterHandle" Value = "@ recombinetics

Kris Huson, Recombinetics, Communications Manager

Copyright Business Wire 2019